Pioglitazone: side effect and safety profile

Standards of Medical Care in Diabetes—2009

2008 • 2,003 citations

A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis

2006 • 1,700 citations

Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus

2007 • 1,240 citations

Physician's desk reference

1987 • 1,036 citations

Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk)

2001 • 1,027 citations

Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure

2003 • 825 citations

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

2005 • 799 citations

Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients

2002 • 684 citations

Rosiglitazone-Associated Fractures in Type 2 Diabetes

2008 • 533 citations

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

2008 • 529 citations

Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

2009 • 494 citations

Bone Is a Target for the Antidiabetic Compound Rosiglitazone

2003 • 454 citations

The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction

2007 • 377 citations

Thiazolidinediones and the Risk of Lung, Prostate, and Colon Cancer in Patients With Diabetes

2007 • 334 citations

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes

2009 • 220 citations

Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications

2003 • 201 citations

Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy.

2000 • 191 citations

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study

2009 • 178 citations

Clinical pharmacokinetics of pioglitazone

2000 • 161 citations

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design

2008 • 158 citations

The pharmacokinetics of pioglitazone in patients with impaired renal function

2003 • 141 citations

Pioglitazone is Metabolised by CYP2C8 and CYP3A4 in vitro: Potential for Interactions with CYP2C8 Inhibitors

2006 • 138 citations

Glitazone Use Associated with Diabetic Macular Edema

2009 • 99 citations

Thiazolidinediones and the risk of edema: A meta-analysis

2006 • 97 citations

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

2007 • 94 citations

Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis

2007 • 87 citations

Reduction in Hematocrit and Hemoglobin Following Pioglitazone Treatment is not Hemodilutional in Type II Diabetes Mellitus

2007 • 82 citations

Weight gain in type 2 diabetes mellitus

2006 • 75 citations

Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone

2009 • 52 citations

Diabetes drug pioglitazone (Actos): risk of fracture

2007 • 52 citations

Bone metabolism in type 2 diabetes and role of thiazolidinediones

2009 • 48 citations

Safety and Efficacy of Low-dose Pioglitazone (7.5 mg/day) vs. Standard-dose Pioglitazone (15 mg/day) in Japanese Women with Type 2 Diabetes Mellitus

2006 • 37 citations

Review article: Importance of the kidney proximal tubular cells in thiazolidinedione‐mediated sodium and water uptake

2009 • 22 citations

Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years

2009 • 8 citations